U.S. Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, Subcutaneous Injection, and Others), by Application (Anti-diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock, Ventricular Tachycardia, and Fibrillation), and by End User (Hospitals, Dental Clinics, and Others), is estimated to be valued at US$ 894.6 million in 2021, and is expected to exhibit a CAGR of 14.7% during the forecast period (2021-2028).
Increasing product launches by market players is anticipated to drive growth of the U.S. vasopressin market over the forecast period. For instance, in May 2020, Dr. Reddy's Laboratories announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. market. Moreover, Dr. Reddy’s Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single dose ampules.
Similarly, in April 2018, Eagle Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for its 1ml vasopressin injection. The product is an original generic version of Endo International plc’s Vasostrict formulation.
U.S. Vasopressin Market- Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
Furthermore, the patients with chronic diseases in the U.S. were not able to visit the healthcare facilities, hampering the treatment of such patients. However, for ensuring continued treatment in the situation of the pandemic, government and healthcare organizations are increasingly focusing on promoting homecare settings. This will provide a convenient and safe solution for such patients without increasing their risk of the infection.
Browse 9 Market Data Tables and 20 Figures spread through 120 Pages and in-depth TOC on U.S. Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, Subcutaneous Injection, and Others), by Application (Anti-diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock, Ventricular Tachycardia, and Fibrillation), and by End User (Hospitals, Dental Clinics, and Others)
To know the latest trends and insights prevalent in the U.S. Vasopressin Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/us-vasopressin-market-4985
Market players are focusing on various inorganic strategies such as collaborations and agreements, which is anticipated to boost the U.S. Vasopressin market growth over the forecast period. For instance, in November 2021, Endo International plc, an Ireland-based pharmaceutical company, announced collaboration of its Par Sterile Products business with Premier, a U.S.-based pharmacy solutions provider, to supply its vasopressin injection, Vasostrict USP (vials) to healthcare providers in the U.S. to help maintain critical care needed during the COVID-19 pandemic.
Key Takeaways of the U.S. Vasopressin Market:
- The U.S. vasopressin market is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028). Growing prevalence of the cardiovascular diseases such as heart attack, coronary artery disease, and others is expected to drive growth of the U.S. vasopressin market over the forecast period. For instance, according to the American College of Cardiology Foundation, in 2019, there were approximately 1.05 million people suffering from coronary diseases in the U.S.
- Among type, intravenous injection segment is expected to witness fastest growth in the U.S. vasopressin market over the forecast period. Market players are engaged in developing a variety of intravenous vasopressin injection available in the market. This is expected to fuel the growth of this segment over the forecast period. For instance, Par Pharmaceutical, a U.S. based pharmaceutical company, offers Vasostrict, an intravenous vasopressin injection to increase blood pressure in patients experiencing vasodilatory shock.
- Some of the major players operating in the U.S. vasopressin market include Par Pharmaceutical, Pfizer Inc., Eagle Pharmaceuticals, Inc., Astellas Pharma Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Athenex, Inc., Otsuka Holdings Co., Ltd, and Azevan Pharmaceuticals, Inc.
